<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255563</url>
  </required_header>
  <id_info>
    <org_study_id>KY20200110-03</org_study_id>
    <nct_id>NCT04255563</nct_id>
  </id_info>
  <brief_title>Drug-coating Balloon Treatment in Coronary Artery Disease</brief_title>
  <acronym>ULTIMATE-DCB</acronym>
  <official_title>Drug-coating Balloon Treatment in Coronary Artery Disease: a Prospective, Multicenter, Registry Study (ULTIMATE-DCB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug-coated balloon (DCB) is an alternative choice for patients with coronary artery disease
      (CAD). This study is to investigate the efficacy and safety of DCB treatment in patients with
      CAD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, registry to enroll patients undergoing DCB treatment.

      All subjects undergoing DCB treatment will be enrolled in this study without strict inclusion
      and exclusion criteria. Data and images will be collected during the index procedure, and at
      the clinical and angiographic follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>target vessel failure (TVF) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>TVF is defined as the composite of cardiac death, target-vessel myocardial infarction and ischemia-driven target- vessel revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parameter by quantitative coronary angiography at 7 months</measure>
    <time_frame>7 months</time_frame>
    <description>Late lumen loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bailout drug-eluting stents (DES) implantation rate</measure>
    <time_frame>During procedure</time_frame>
    <description>Bailout DES implantation rate during procedure by angiographic criteria</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>DCB treatment</arm_group_label>
    <description>DCB (Sequent® Please) treatment will be performed for suitable patients with CAD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DCB treatment</intervention_name>
    <description>DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.</description>
    <arm_group_label>DCB treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects with coronary artery disease undergoing DCB treatment will be enrolled in this
        study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suitable for DCB treatment

        Exclusion Criteria:

          -  Pregnancy

          -  Contraindications to contrast media, antiplatelet therapy, or paclitaxel

          -  Expected life less than 12 months

          -  Cardiac shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shao-Liang Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun-Jie Zhang, MD</last_name>
    <phone>025-52271350</phone>
    <email>jameszll@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao-Fei Gao, MD</last_name>
    <phone>025-52271350</phone>
    <email>gaoxiaofei2014@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoliang Chen, MD</last_name>
      <phone>13605157029</phone>
      <email>chmengx@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Junjie Zhang</investigator_full_name>
    <investigator_title>Vice chief of the department of cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

